Nitrile derivatives that inhibit cathepsin K

US6531612B2 · kind B2 · utility

Assignee

• Hoffmann-La Roche Inc. · US

Inventors

• Tobias Gabriel · Basel, CH
• Michael Pech · Hartheim, DE
• Sabine Wallbaum · Esslingen am Neckar, DE

Key dates

• Filing date: Dec 21, 2000
• Grant date: Mar 11, 2003
• Expiry date: Dec 21, 2020

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of the formula: wherein R1 to R7 and Y are as defined in the specification, and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof, are useful for treating diseases associated with cystein proteases, such as osteoporosis, osteoarthritis, rheumatoid arthritis, tumor metastasis, glomerulonephritis, atherosclerosis, myocardial infarction, angina pectoris, instable angina pectoris, stroke, plaque rupture, transient ischemic attacks, amaurosis fugax, peripheral arterial occlusive disease, restenosis after angioplasty and stent placement, abdominal aortic aneurysm formation, inflammation, autoimmune disease, malaria, ocular fundus tissue cytopathy and respiratory disease.